Drug Search Results
More Filters [+]

Seltorexant

Alternative Names: seltorexant, jnj-42847922, jnj-922, jnj 42847922, jnj42847922, min-202, min202
Latest Update: 2024-08-19
Latest Update Note: Clinical Trial Update

Product Description

Johnson & Johnson is developing Seltorexant as a treatment for major depressive disorder with insomnia symptoms. (Sourced from: https://www.investor.jnj.com/pipeline/development-pipeline/default.aspx)

Mechanisms of Action: OX2R Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Seltorexant

Countries in Clinic: Argentina, Belgium, Brazil, Bulgaria, Canada, Colombia, Czech Republic, Germany, Latvia, Lithuania, Malaysia, Mexico, Netherlands, Poland, Russia, Serbia, Slovakia, South Africa, Spain, Sweden, Taiwan, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 13

Highest Development Phases

Phase 3: Depressive Disorder, Major

Phase 2: Alzheimer Disease|Insomnia

Phase 1: Healthy Volunteers|Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

42847922MDD3003

P3

Recruiting

Depressive Disorder, Major

2026-12-30

CR109177

P2

Completed

Alzheimer Disease

2023-11-10

32%

CR108810

P3

Completed

Depressive Disorder, Major

2023-10-03

CR109099

P1

Completed

Healthy Volunteers

2023-05-12

28%

Recent News Events